ClinicalTrials.gg
CompletedNCT07937709Updated Nov 16, 2026

CAROTID STABILISE Pilot: Alirocumab for Symptomatic Carotid Stenosis

A Phase 2 interventional study of Alirocumab and Matching placebo in Carotid Artery Stenosis, sponsored by Middle East North Africa Stroke and Interventional Neurotherapies Organization. Completed at 5 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Middle East North Africa Stroke and Interventional Neurotherapies Organization · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jan 2026, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

CAROTID STABILISE Pilot tested whether adding alirocumab to high-intensity atorvastatin changes high-risk plaque features in people recently affected by a stroke or transient ischemic attack (TIA) related to carotid artery narrowing. Forty adults aged 40-80 years were randomly assigned in equal groups to alirocumab 150 mg injected under the skin every two weeks or matching placebo every two weeks; both groups took atorvastatin 80 mg daily for 26 weeks. The main outcome was change from baseline to week 26 in intraplaque haemorrhage (IPH) volume measured by high-resolution carotid MRI. Other outcomes included changes in plaque features and LDL cholesterol, safety events, and exploratory recurrent ischemic events or carotid revascularisation. The study was conducted at five sites-four in Egypt and one in Istanbul, Türkiye-and completed on 26 August 2026. This ClinicalTrials.gov record is being submitted retrospectively after study completion; prospective registration on ClinicalTrials.gov is not claimed.

Read the detailed description

CAROTID STABILISE Pilot was a prospective, multicentre, randomized, double-blind, placebo-controlled, parallel-group pilot trial conducted at five sites: four in Egypt and one in Istanbul, Türkiye. Forty adults aged 40-80 years with recently symptomatic carotid stenosis and high-risk plaque features on MRI were assigned 1:1 to alirocumab 150 mg subcutaneously every two weeks plus atorvastatin 80 mg orally once daily, or matched placebo plus atorvastatin 80 mg orally once daily, for 26 weeks. The protocol described quadruple masking of participants, care providers, investigators, and outcome assessors. The primary outcome was absolute change in carotid intraplaque haemorrhage (IPH) volume from baseline to week 26, measured in mm³ by 3T high-resolution vessel-wall MRI with blinded central assessment. Secondary outcomes included percentage change in IPH volume; absolute and percentage change in lipid-rich necrotic core volume; change in total wall plaque volume and plaque burden; and change in LDL cholesterol and other lipid parameters. Safety outcomes included treatment-emergent adverse events, serious adverse events, and injection-site reactions. Exploratory clinical assessments included recurrent ipsilateral ischemic stroke or TIA and carotid revascularisation. Signed and approved Amendment 1-Clarification/Correction, document MENASINO-CAROTID-PILOT-AMD1, Version 1.0, dated and effective 1 December 2025, states that this 40-participant pilot is a separate stand-alone trial, has separate ethics approvals and registration, and is excluded from parent Phase III trial NCT07586540. The pilot enrolled participants beginning 6 January 2026; the final week-26 MRI assessment and final required safety follow-up occurred on 26 August 2026. This ClinicalTrials.gov record is being submitted retrospectively after enrollment and follow-up were complete. The study was not prospectively registered on ClinicalTrials.gov, and no claim of prospective ClinicalTrials.gov registration is made.

02

Conditions studied

  • Carotid Artery Stenosis

Browse trials for

03

In context

Carotid Stenosis

366 studies on the registry are indexed under Carotid Stenosis; 86 are open to participants now.

This study's enrollment of 40 is below the median of 103 across 191 interventional studies indexed under Carotid Stenosis.

Browse Carotid Stenosis studies →

Lead sponsor

Middle East North Africa Stroke and Interventional Neurotherapies Organization is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 40-80 years.
  2. Ipsilateral carotid-territory ischaemic stroke or (TIA) within 30 days before randomisation.
  3. A non-disabling qualifying event, defined as a Modified Rankin Scale score of 2 or less or a National Institutes of Health Stroke Scale score of 4 or less at randomisation.
  4. Symptomatic internal carotid artery stenosis of 50-99% by NASCET criteria.
  5. High-resolution vessel-wall MRI showing intraplaque haemorrhage (IPH) or lipid-rich necrotic core (LRNC) comprising at least 30% of plaque volume.
  6. Written .

Exclusion criteria

Exclusion Criteria:

  1. An indication for urgent carotid revascularisation.
  2. Stenosis of at least 70% with high-risk features requiring surgery under the applicable local guideline.
  3. A cardioembolic source of the qualifying event.
  4. Recent intracranial haemorrhage.
  5. Estimated below 30.
  6. Active liver disease.
  7. Previous PCSK9 inhibitor use.
  8. to MRI.
  9. Contraindication to alirocumab.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Alirocumab 150 mg every 2 weeks

    Alirocumab 150 mg by subcutaneous injection every 2 weeks for 26 weeks, with atorvastatin 80 mg orally once daily as background therapy.

    Drug: Alirocumab

  • Placebo comparator
    Matched placebo every 2 weeks

    Matched placebo by subcutaneous injection every 2 weeks for 26 weeks, with atorvastatin 80 mg orally once daily as background therapy.

    Drug: Matching placebo

Interventions

  • Alirocumab 150 mg administered by subcutaneous injection every 2 weeks for 26 weeks. Participants also received atorvastatin 80 mg orally once daily as background therapy.

  • DrugMatching placebo

    Matching placebo administered by subcutaneous injection every 2 weeks for 26 weeks. Participants also received atorvastatin 80 mg orally once daily as background therapy.

06

What researchers measure

Primary outcomes

  1. Absolute change in carotid intraplaque haemorrhage (IPH) volume

    Change in IPH volume (week 26 minus baseline), measured in mm³ by 3T high-resolution vessel-wall MRI and assessed by a blinded central imaging laboratory. Negative values indicate a decrease in IPH volume.

    Time frame: Baseline to Week 26

Secondary outcomes

  1. Percentage change in carotid intraplaque haemorrhage (IPH) volume

    Percentage change in IPH volume from baseline to week 26, assessed by 3T high-resolution vessel-wall MRI with blinded central imaging assessment.

    Time frame: Baseline to Week 26

  2. Absolute change in carotid lipid-rich necrotic core (LRNC) volume

    Absolute change in LRNC volume from baseline to week 26, measured by high-resolution carotid MRI and blinded central imaging assessment.

    Time frame: Baseline to Week 26

  3. Percentage change in carotid lipid-rich necrotic core (LRNC) volume

    Percentage change in LRNC volume from baseline to week 26, assessed on high-resolution carotid MRI with blinded central imaging assessment.

    Time frame: Baseline to Week 26

  4. Change in total carotid wall plaque volume

    Change in total wall plaque volume from baseline to week 26, measured in mm³ by high-resolution carotid MRI with blinded central imaging assessment.

    Time frame: Baseline to Week 26

  5. Change in carotid plaque burden

    Change in plaque burden, expressed in percentage points, from baseline to week 26 and assessed by high-resolution carotid MRI.

    Time frame: Baseline to Week 26

  6. Change in LDL cholesterol and other lipid parameters

    Change in LDL cholesterol (absolute and percentage change) and other lipid parameters, including total cholesterol, from baseline to week 26.

    Time frame: Baseline to Week 26

Other outcomes

  1. Treatment-emergent adverse events and serious adverse events

    Number of participants experiencing treatment-emergent adverse events, serious adverse events, or injection-site reactions during the study period.

    Time frame: From first study treatment through Week 26

  2. Exploratory ipsilateral recurrent ischemic stroke or TIA and carotid revascularisation

    Occurrence of ipsilateral recurrent ischemic stroke or TIA and carotid revascularisation through week 26. These exploratory clinical events were not powered for efficacy.

    Time frame: Randomization through Week 26

07

Study locations

5 sites
  • Alexandria University Main Hospital
    Alexandria, Egypt
  • Ain Shams University Specialized Hospital
    Cairo, Egypt
  • Al-Azhar University
    Cairo, Egypt
  • Tanta University Teaching Hospital
    Tanta, Egypt
  • Neurology Department, Dr. Lutfi Kirdar City Hospital
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Aug 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Jan 6, 2026
Primary completionActual
Aug 26, 2026
CompletionActual
Aug 26, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937709
Lead sponsor
Middle East North Africa Stroke and Interventional Neurotherapies Organization
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 6, 2026
Primary completion
Aug 26, 2026
Completion
Aug 26, 2026
Last update
Nov 16, 2026

Study contacts

Ossama Y Mansour, MD, PhD
principal investigator · Stroke & Neurointervention Unit, Alexandria University School of Medicine, Alexandria, Egypt

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion